New Delhi: Drug firm Ranbaxy Laboratories
today said its Romanian arm will market Daiichi Sankyo's drug
Evista, used in treatment of osteoporosis, in the European
country.
Terapia SA (Terapia Ranbaxy), a Romania-based subsidiary
of the company, would market the osteoporosis medication drug
in the country and it is for the first time that Ranbaxy is
going to market Daiichi's product in the overseas market.
"This is the first time in Europe that Daiichi Sankyo
and Ranbaxy are leveraging synerigies generated through the
hybird business model," Ranbaxy Laboratories, in which Japan's
third largest drug maker Daiichi Sankyo has 64 per cent stake,
said in a statement.
In March this year, Ranbaxy introduced anti-hypertensive
drug Ovlance from the parent company's portfolio in India.
"Terapia Ranbaxy is a strong player in Europe, and we
will provide a unique platform to Daiichi Sankyo for the
launch of Evista, and many more new products in the future,"
Ranbaxy CEO and Managing Director Atul Sobti said.
Terapia Ranbaxy is the largest generic pharmaceutical
company in Romania and is one of the seven largest drug firms
in the country.
Bureau Report
First Published: Tuesday, September 01, 2009, 21:13